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Abstract
Purpose The study evaluated whether the dual
blockade of the renin–angiotensin system may influ-
ence the sodium balance in hemodialysis.
Methods The study involved 148 hemodialysis
patients (male 85, female 63), mean age 59.6 ± 12.9
years. Participants were randomly selected to receive
either angiotensin-converting enzyme inhibitor
(ACEI)—subgroup A—or dual blockade ACEI and
angiotensin receptor blocker (ARB)—subgroup AA.
Results At baseline, in the A versus AA subgroups,
the pre-dialysis sodium concentrations (mmol/l) were
137.7 ± 0.5 versus 137.9 ± 0.8, the sodium gradients
2.6 ± 0.5 versus 2.9 ± 0.4, interdialytic weight gain
(IWG) (kg) 3.1 ± 0.2 versus 3.0 ± 0.3, and thirst
inventory score (points) 18.1 ± 1.0 versus 19.0 ± 1.7,
respectively. After 3 months of therapy, a decrease in
sodium concentration to 134.5 ± 0.5 and the increase
of its gradient to 5.5 ± 0.5 were noted in the AA
subgroup. An elevation of mean interdialytic weight
gain to 3.47 ± 0.2 and thirst score to 21.3 ± 2.1 was
observed. No significant changes in subgroup A were
found. One month of the dialysate sodium concentration
being lowered from 140 mmol/l to 138 mmol/l was
associated with reduced serum sodium concentration
and gradient, decreased IWG and restored moderate
thirst score in the AA subgroup (137.5 ± 0.6 and
2.9 ± 0.6, 3.0 ± 0.5 and 19.2 ± 1.3, respectively).
Conclusions The dual blockade of the renin–angio-
tensin system affects sodium balance, increasing the
sodium gradient, thus elevating thirst sensation and
enhancing interdialytic weight gain. In maintenance
hemodialysis patients treated with both ACEI and ARB,
lowered dialysate sodium levels should be prescribed.
Keywords Serum angiotensin-converting enzyme
inhibitors  Angiotensin receptor blockers  Sodium
concentration  Sodium gradient  Hemodialysis 
Interdialytic weight gain  Thirst inventory
Introduction
Intermittent hemodialysis (HD) is the most commonly
used renal replacement modality. During thrice-
weekly sessions, the proper fluid volume balance
must be restored. One way of doing this is by
preserving the optimum sodium balance, which
depends mainly on dietary salt intake and sodium
removal during HD sessions [1]. With this in mind,
increased dietary sodium ingestion is believed to be
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the main determinant of interdialytic weight gain in
HD patients without hyperglycemia [2]. It leads to
uncontrolled thirst, thus provoking fluid consumption
and excessive weight gain [1, 3]. Chronic overhydra-
tion linked to sodium imbalance shows a number of
cardiovascular manifestations and other complications
such as chronic hemodilution and dilutional anemia,
not to mention hypertension, while its reversal results
in a decrease in morbidity and mortality [3–6].
The pathogenesis of thirst has not been clearly
defined. Nevertheless, renin–angiotensin cascade
activity, among other factors, may play a role by
increasing sodium appetite [7]. Well-known antihy-
pertensive drugs such as angiotensin-converting
enzyme inhibitors (ACEI) and angiotensin receptor
blockers (ARB) may reduce fluid intake and suppress
drinking behavior in hemodialysis patients, though
this has yet to be confirmed [8–10]. Although their
thirst-reducing potential has been widely discussed,
the mechanism of their action has not been investi-
gated. Hence, we assume that sodium imbalance plays
a key role in the treatment of excessive thirst and
interdialytic excessive weight gain with ACEI and
ARB.
The aim of the study was, therefore, to determine
whether the dual blockade of renin–angiotensin sys-
tem may influence the sodium balance in hemodialysis
patients and subsequently affect thirst or interdialytic
weight gain.
Materials and methods
A prospective, randomized, open-label trial was
conducted in 148 hemodialysis patients (male 85,
female 63), mean age 59.6 ± 12.9 years. The mean
time from starting hemodialysis was 13.5 ± 6.7
months. All subjects were recruited from the Dialysis
Department of the Norbert Barlicki Memorial Teach-
ing Hospital No. 1. The mean session time was 4 h
and 15 min. The causes of end-stage renal disease
included chronic glomerulonephritis in 36 patients,
diabetic nephropathy in 55, adult polycystic kidney
disease in 10, hypertension in 13, tubulointerstitial
nephritis in 21, and unknown in 13 patients. The
eligibility criteria for a patient to be included in the
study were as follows: age between 18 and 80 years
old, a fixed hemodialysis schedule of 3 times a week,
and a stable clinical condition. The exclusion criteria
comprised uncontrolled hypertension or recurrent
symptomatic hypotension episodes, chronic heart
failure (NYHA stage 4), severe acute infections
requiring hospitalization and the administration of
centrally acting sympathicolytics. All patients were
advised to maintain their usual dietary habits.
Participants were divided into a study group—
hypertensive patients (treated with combination of
antihypertensive medication from 1 to 3 of type) and a
control group—normotensive patients. Of the study
group, two subgroups were formed by random selec-
tion of the hypertensive patients. The first (subgroup
A) received a mean dose of 10 mg (single morning
dose) of ACEI, that is, ramipril, while the second
(subgroup AA) received a mean dose of 5 mg of
ramipril in the morning and ARB, that is, losartan—a
mean dose 50 mg—in the evening. These treatments
allowed blood pressure below 140/90 mmHg before
and 130/80 mmHg after hemodialysis to be achieved
in all of the participants [11]. In both subgroups,
antihypertensive treatment was not changed and
doses were stable for the 4-month duration of the
study.
The kidney replacement therapy was conducted on
Fresenius 4008 dialysis machines exclusively. Stan-
dard bicarbonate dialysate fluid containing 140 mmol/
l of sodium, 1.25 mmol/l of calcium, and 0.75 mmol/l
of magnesium was used. The potassium concentration
varied depending on the degree of the patient’s
kalemia before the session. The dialysis adequacy
was assessed with a single-pooled kT/V of average
value 1.1–1.3. The dry weight was established based
on clinical examination, blood pressure measure-
ments, and whole-body composition spectroscopy
[12]. The dialysis prescription did not change within
4 months of the study, except in the case of subgroup
AA, in which the dialysate sodium concentration was
reduced to 138 mmol/l after 3 months of ACEI and
ARB therapy.
At baseline and after 3 and 4 months of the study on
a second mid-week dialysis session, pre- and post-
dialysis sodium concentration and sodium gradient
were assessed. All measurements were carried out
routinely in certified central hospital laboratory auto-
matic analyzers. Interdialytic weight gain, defined as
the difference between current body mass and dry
weight (IWG), and blood pressure (BP) were mea-
sured before each hemodialysis, and the mean IWG
and BP at every stage of the study were computed.
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Additionally, all participants completed a survey
evaluating thirst intensity. The dialysis thirst inventory
is a questionnaire which consisted of 7 items, each
with a 5-point Likert scale ranging from never (1) to
always (5). The results ranged from a minimum 7
points (no thirst) to a maximum 35 points (enormous
thirst). The thirst questionnaire was conducted
together with the biochemical tests.
In all of participants, the mineral bone disorder
associated with their renal anemia and kidney diseases
was successfully treated according to the National
Kidney Foundation Disease Outcomes Quality Initia-
tive (NKF–KDOQI) recommendations [13, 14] as was
diabetes mellitus [15]. The study and the control
groups were age and sex matched, and significant
parameters including mean hemoglobin, number of
participants with preserved residual urination or
diabetes, and mean session time were comparable.
The results are summarized in Table 1.
Statistical analysis
The normality of distribution was checked by the
Kolmogorov–Smirnov test. Comparisons within and
between the study group and subgroups were per-
formed using three-way ANOVA. The Fisher’s exact
probability test was used for gender comparison.
Differences were considered significant if p was
\0.05. The results were expressed as mean ± stan-
dard deviation. Statistical analysis was performed
using Statistica for Windows software (version 10.0).
We conducted our study in compliance with the
principles of the Helsinki Declaration. The study
protocol was approved by the Medical University of
Lodz Bioethics Committee, Resolution Number RNN
147/09/KE. According to principles of good clinical
practice (GCP), the informed consents have been




At baseline pre- and post-dialysis, sodium serum
concentrations were similar in the subgroups and in
the control group (p [ 0.05 for all comparisons).
After 3 months of treatment, pre-dialysis Na rapidly
decreased in the AA subgroup. No changes in
sodium concentration in other groups were
observed. The correction of Na in dialysate resulted
in restoring a balanced serum sodium concentration
in the AA subgroup. All results are shown in
Tables 2, 3, and 4.
Sodium gradient
The initial pre- and post-dialysis sodium gradients
were comparable in the study and control groups.
Although a dual blockade of the renin–angiotensin
system was seen to significantly increase pre- and
post-dialysis sodium gradients in month 3 of treat-
ment, the reduction of dialysate sodium decreased Na
gradients in the AA subgroup. The results are collected
in Tables 2, 3, and 4.
Table 1 Structure and
clinical characteristic of the





mean ± standard deviation
(SD)
Study group Control group
Subgroup A Subgroup AA
N 47 47 54
Male (n) 28 29 28
Age (years) 60.1 ± 15.9 59.9 ± 11.5 58.5 ± 13.3
Diabetes (n) 18 19 22
HbA1c (%) 6.4 ± 0.6 6.6 ± 0.3 6.5 ± 0.4
Hemodialysis vintage (months) 11.1 ± 6.6 10.4 ± 5.3 10.1 ± 6.9
Dialysis session time (minutes) 250 ± 15 245 ± 20 255 ± 25
Kt/V 1.22 ± 0.12 1.21 ± 0.1 1.2 ± 0.08
Hgb (g/dl) 10.5 ± .1.2 10.9 ± 1.6 10.7 ± 1.3
Residual diuresis (n) 10 10 13
Volume (ml/day) 710 ± 110 690 ± 120 700 ± 140
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Blood pressure, interdialytic weight gain,
and thirst
At baseline, mean systolic and diasystolic blood
pressure in hypertensive patients (subgroups A vs.
AA) were similar. After 3 months of therapy with
ACEI and ARB, blood pressure did not change,
although systolic BP was significantly higher than in
patients in subgroup A (p \ 0.01). Although at the end
of the study (month 4) blood pressure was comparable
in both subgroups (p [ 0.05) and systolic BP in
subgroup, AA was significantly decreased in compar-
ison with month 3 (p \ 0.05). Twenty-six hypotension
episodes, defined as a fall of BP below 90 mmHg or a
decrease C20 mmHg from the pre-dialysis blood
pressure, were observed in subgroup AA during the
Table 2 Parameters at
baseline
Values are
mean ± standard deviation
(SD)
Study group Control group
Subgroup A Subgroup AA
Pre-dialysis Na (mmol/l) 137.7 ± 0.5 137.9 ± 0.8 137.7 ± 0.6
Post-dialysis Na (mmol/l) 138.3 ± 0.3 137.7 ± 0.6 138.2 ± 0.4
Pre-dialysis Na gradient 2.6 ± 0.5 2.9 ± 0.4 2.7 ± 0.6
Post-dialysis Na gradient 2.1 ± 0.5 2.0 ± 0.3 1.94 ± 0.5
Interdialytic weight gain (kg) 3.1 ± 0.2 3.0 ± 0.3 2.97 ± 0.4
Thirst score (pts) 18.1 ± 1.0 19.0 ± 1.7 18.6 ± 1.6
Systolic pressure (mmHg) 127 ± 12 128 ± 14 122 ± 9
Diasystolic pressure (mmHg) 78 ± 17 79 ± 12 76 ± 10
Table 3 Parameters after
3 months of treatment
Values are
mean ± standard deviation
(SD)
ANOVA statistical




Study group Control group
Subgroup A Subgroup AA
Pre-dialysis Na (mmol/l) 137.5 ± 0.4* 134.5 ± 0.5*’** 137.5 ± 0.7**
Post-dialysis Na (mmol/l) 138.0 ± 0.4* 136.5 ± 0.3*’** 138.1 ± 0.3**
Pre-dialysis Na gradient 2.46 ± 0.4* 5.5 ± 0.5*’** 2.3 ± 0.7**
Post-dialysis Na gradient 1.96 ± 0.4* 3.5 ± 0.2*’** 1.86 ± 0.3**
Interdialytic weight gain (kg) 2.85 ± 0.1* 3.47 ± 0.2*’** 2.91 ± 0.3**
Thirst score (pts) 17.6 ± 1.1* 21.3 ± 2.1*’** 18.4 ± 1.4**
Systolic pressure (mmHg) 125 ± 11* 130 ± 10*’** 124 ± 14**
Diasystolic pressure (mmHg) 75 ± 14 78 ± 13 76 ± 12
Table 4 Parameters at the
end of fourth month
Values are
mean ± standard deviation
(SD)
Study group Control group
Subgroup A Subgroup AA
Pre-dialysis Na (mmol/l) 137.2 ± 0.4 137.5 ± 0.6 137.4 ± 0.7
Post-dialysis Na (mmol/l) 138.1 ± 0.2 137.9 ± 0.5 138.1 ± 0.6
Pre-dialysis Na gradient 2.8 ± 0.7 2.9 ± 0.6 2.8 ± 0.8
Post-dialysis Na gradient 2.2 ± 0.5 2.1 ± 0.4 2.0 ± 0.3
Interdialytic weight gain (kg) 2.9 ± 0.2 3.0 ± 0.5 2.9 ± 0.4
Thirst score (pts) 19.1 ± 1.1 19.2 ± 1.3 18.8 ± 1.2
Systolic pressure (mmHg) 125 ± 13 127 ± 15 122 ± 10
Diasystolic pressure (mmHg) 76 ± 12 77 ± 13 75 ± 8
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trial. In patients treated with a single blockade (ACEI),
twenty-one hypotension episodes were noted. This
difference was not found to be statistically significant.
The mean interdialytic weight in subgroup A did
not differ at baseline in comparison with AA but after
3 months of therapy in patients with dual blockade,
IWG was raised (p \ 0.05) and was significantly
higher in subgroup AA than in subgroup A (p \ 0.01).
At the end of the study, the mean IWG of the
subjects in subgroup AA was comparable to that of
subgroup A and to results noted in AA at baseline (all
p [ 0.05).
The initial mean thirst scores did not differ
significantly between subgroups (p [ 0.05); however,
an assessment after 3 months of treatment indicated a
significant increase in the AA subgroup (p \ 0.05). In
comparison with the control and subgroup A, the mean
thirst score was significantly higher (p \ 0.01). At the
end of the treatment period, no differences between
study groups and baseline results were observed
(p [ 0.05).
All results are presented in Tables 2, 3, and 4.
Figure 1 shows the changes in pre-dialysis serum
sodium and sodium gradient, interdialytic weight gain,
and thirst sensation score in AA subgroup with the
sodium dialysate prescription changes in the
background.
Discussion
Since excessive thirst and IWG were first defined as
being strictly connected items which commonly occur
in hemodialysis patients [16], various intervention
strategies have been evaluated [8, 10, 17].
The influence of ACEI on IWG and thirst has been
widely examined, and it was believed to play a
positive role in the reduction of IWG [8, 10] although
with some reservations [17]. Unfortunately, earlier
studies had many limitations: mainly small numbers of
participants or no wash-out period.
Also, some studies attempted to establish whether
therapy with angiotensin receptor blockers (ARB)
could reduce thirst and IWG [10]. Although the
effectiveness of ACEI use in the reduction of thirst and
IWG may be open for discussion, ARB seems to be
ineffective [10, 18]. The only confirmed effect of
ACEI and ARB administration was a reduction in
angiotensin II and aldosterone level, as well as pseudo-
normalization after drug withdrawal [8, 10]. Further-
more, studies on the administration of angiotensin
receptor antagonists in hemodialysis patients are
unsatisfactory due to their limited scope, in that they
focus mainly on their safety [19].
Although the dual RAA blockade is not commonly
administered, there are good theoretical reasons why
Fig. 1 The changes in pre-
dialysis serum sodium and
sodium gradient,
interdialytic weight gain and
thirst sensation score in AA
subgroup with the sodium
dialysate prescription
changes in the background
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combination therapy with ACEI inhibitors, and the use
of ARB to block the binding of angiotensin II with its
receptor, provides a more complete blockade of
angiotensin effects. The ValHeFT study analyzed the
benefits of the addition of valsartan to ACE inhibitor in
3034 chronic heart failure (CHF) patients [20]. It
showed a significant decrease in the morbidity
endpoints [20] and resulted in the reduction of
cardiovascular death and hospitalization rates [20,
21]. Fluid overload and secondary CHF due to left
ventricle hypertrophy are typical of maintaining
hemodialysis patients, particularly in interdialysis
periods, so that the introduction of a dual RAA
blockade to those patients may be beneficial.
The decrease in renal salt and water excretion may
lead to hypertension and, particularly, hypervolemia
[1, 3] as well as thirst and fluid overload [22] in
hemodialysis patients, while a reduction of dialysate
sodium or dietary intake should, hence, improve the
patient’s status. However, the important question is
whether the reduction is beneficial to all dialysis
patients, including those who are normotensive, those
who are hypotensive, and those who lose renal salt
[23]. Some authors indicate that no controlled studies
of sufficient quality are available [24]. Therefore, it
remains unclear what the most appropriate strategies
for optimizing sodium corrections are and for whom
they would be beneficial.
In our study, at baseline, the dialysate sodium
concentration was set at 140 mmol/l, which generated
a positive pre- and post-dialysis dialysate to the
plasma sodium gradients which ranged from 2.6 in
subgroup A to 2.9 in subgroup AA. Such a reduced Na
gradient is associated with a significantly reduced
thirst score and interdialytic weight gain [25, 26] and
does not exacerbate intradialytic hypotension [27, 28].
After 3 months of treatment with a dual blockade of
the renin–angiotensin system, pre- and post-dialysis
sodium serum concentrations were lower than at
baseline and decreased in subgroup AA in comparison
with subgroup A and the control group. As a result,
computed pre- and post-dialysis sodium gradients
were higher. To maintain the osmolar set point, a
positive dialysate to plasma Na gradient of over
3 mEq/l is associated with sodium retention and
proportional fluid ingestion [26, 29]. Furthermore,
the thirst score was increased up to a mean of 21.3
points, that is, from moderate to high, and elevated in
comparison with the findings from subgroup A and the
control group. Subsequently in the AA subgroup, an
increase in mean IWG was observed, and despite a
more efficient dual blockade of the renin–angiotensin
system, elevated values for mean systolic blood
pressure were noted.
A possible reason for these observations is that the
introduction of ARB to the treatment impairs the
sodium balance and switches the sodium set point,
increasing its gradient and inducing post-dialysis thirst
sensation and excessive fluid ingestion, thus leading to
hypervolemia. It is worth noting that sodium removal
during hemodialysis relies on both convective losses
(78 %) and diffusive losses (22 %) [25]. In addition,
increased IWG was found to result in sodium dilution
and augmented ultrafiltration in the AA subgroup.
Furthermore, enhanced IWG itself leads to a progres-
sive increase of the sodium gradient.
Several studies have shown the ability of angioten-
sin-converting enzyme inhibitors to suppress thirst and
effectively reduce interdialytic weight gain by mod-
ifying improper drinking behaviors in maintaining
hemodialysis patients [8, 9]. In contrast, Masajtis et al.
showed that adding an ARB to chronic ACEI therapy
did not reduce the thirst sensation nor IWG in those
patients [10].
Lack of effectiveness of ARB therapy in reducing
thirst may play a pivotal role in both the increased
IWG and lower pre-dialysis serum sodium concentra-
tions noticed in our AA subgroup (those subjected to
ACEI and ARB treatment). The double blockade of
RAA has two further effects: not only does it increase
plasma renin activity, but it also raises the angiotensin
II serum concentration: Angiotensin II is synthesized
by chymases (the angiotensin escape phenomenon)
and cannot be bound to receptors already blocked by
ARB. All of these factors exacerbate the thirst felt by
hemodialysis patients [30, 31]. The consequent exces-
sive water consumption by the patient may lead to
electrolyte dilution and lower serum sodium concen-
tration as a result.
Interestingly, a 1-month prescription of 138 mmol/l
dialysate sodium allowed sodium balance normaliza-
tion to be achieved, average interdialytic weight gain
to be restored, thirst score to be reduced, and systolic
blood pressure to be decreased. No further changes in
antihypertensive treatment were needed.
However, there is still a need to explain the paradox
of the ‘‘reversed’’ effect of a lowered sodium concen-
tration in the dialysate: the greater the sodium
1370 Int Urol Nephrol (2013) 45:1365–1372
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gradient, the higher the IWG value [25, 26]. The
reduction of sodium in the dialysate normalizes its
gradient, which diminishes the sensation of thirst and
excessive drinking related to the lowered serum
sodium concentration due to serum dilution. An
adjustment of dialysate sodium level seems to lead
to stabilization of sodium levels in the serum, which
would explain the nature of the decreased sodium
gradient seen in subgroup AA, and its impact on the
variables assessed in this study. This observation also
confirms that a proper sodium gradient is of impor-
tance in helping chronic dialysis patients to maintain a
correct sodium balance and prevent excessive fluid
intake [32].
Study limitations
The open-label design of the study. Also, the admin-
istration of numerous drugs may influence the thirst,
IWG, and sodium balance [33]; for that reason, no
changes in concomitant medications in any of subjects
were made. The thirst assessment based on the dialysis
thirst inventory was performed without an evaluation
of xerostomia; however, we assumed that thirst is a
subjective feeling and self-reporting methods seem to
be the most appropriate.
Conclusions
The dual blockade of the renin–angiotensin system
affects sodium balance, increasing the sodium gradi-
ent, thus elevating thirst sensation and enhancing
interdialytic weight gain. In maintenance hemodialy-
sis patients treated with both ACEI and ARB, lowered
dialysate sodium concentration should be prescribed.
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